Despite its clinical importance, the global ICP monitoring market remains small, slow-growing, and resistant to disruption.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has shared new proposals intended to improve access to the latest medical device technologies for UK patients.

Healthcare investment company ARCHIMED’s affiliate is set to acquire ZimVie for an enterprise value of around $730m.

The implications of medical device regulations on market entry strategies are profound. Credit: Doidam 10/Shutterstock.com. The medical devices industry is always undergoing significant regulatory ...

The US Court of Appeals has overturned a $106.5m ruling wherein a California court jury found that Medtronic infringed on a heart valve replacement method developed by Colibri Heart Valve.

DeepQure has secured approval from South Korea's MFDS for the trial of its HyperQure, aimed at treating atrial fibrillation (AF).

RadNet's subsidiary DeepHealth has concluded the previously announced acquisition of iCAD in a deal valued at $103m.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Saluda Medical has announced the full US commercial launch of its EVA sensing technology intended for scanning and analysing the spinal cord.

Xeltis has reported positive preliminary data for its Xabg coronary artery bypass conduit (CABG) in a trial that is underway at EU sites.

Medtronic has announced the first subject enrolment in the PELE trial, aiming to assess the Onyx liquid embolic system (LES).

The medical device industry faces being pulled into a broader contest over control, sovereignty and industrial self-sufficiency.